Security Snapshot

Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD) Institutional Ownership

CUSIP: 67577R102

13F Institutional Holders and Ownership History from Q4 2020 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

78

Shares (Excl. Options)

65.32MFull value: 65,316,626 · shares · 30 Sep 2026

Price

$4.84

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+16,858,547
Value change
+$82,682,604
Number of holders
78
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
100,966,216
SEC-reported price per share
$4.10
Insider filing price
$4.10
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • IRD - Opus Genetics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 67577R102.
  • 78 institutions reported positions in Q3 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 103 to 78 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $236.38MFull value: $236,380,475 · USD · 30 Jun 2026
    to
    $316.12MFull value: $316,118,732 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 78 institutions filings for Q3 2026.

Open SEC evidence

Security key

67577R102

13F reference period

Q3 2026

13F holders

78

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
IRD
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
PERCEPTIVE ADVISORS LLC 10% 0% $41,354,752 +$3,496,542 10,086,525 +9.2% Perceptive Advisors LLC 30 Sep 2026
BALYASNY ASSET MANAGEMENT L.P. 7.4% +10% $25,952,964 +$2,716,873 6,120,982 +12% BALYASNY ASSET MANAGEMENT L.P. 30 Sep 2026
Caligan Partners LP 6.2% -16% $24,439,985 -$476,059 5,960,972 -1.9% Caligan Partners LP 30 Sep 2026
Cormorant Asset Management, LP 6.6% $23,320,000 5,500,000 Cormorant Asset Management, LP 30 Sep 2026
BlackRock, Inc. 6.1% $24,417,059 5,044,847 BlackRock, Inc. 30 Sep 2026
Nantahala Capital Management, LLC 6.5% -35% $23,808,987 -$11,238,663 4,839,225 -32% Nantahala Capital Management, LLC 31 Mar 2026
Boxer Capital Management, LLC 5.4% $18,588,006 4,533,660 Boxer Capital Management, LLC 30 Sep 2026
Foundation Fighting Blindness Retinal Degeneration Fund 4.7% -42% $17,709,439 -$7,939,000 3,792,171 -31% Foundation Fighting Blindness Retinal Degeneration Fund 18 May 2026
BIOS Fund III, LP 4.5% $18,122,471 3,683,429 AARON G.L. FLETCHER 12 May 2026
Adage Capital Management, L.P. 2.7% -72% $9,561,183 -$16,005,063 2,254,996 -63% Adage Capital Management, L.P. 30 Sep 2026
As of 30 Sep 2026, 78 institutional investors reported holding
65.32MFull value: 65,316,626 · shares · 30 Sep 2026
shares of Opus Genetics, Inc. - Common Stock, $0.0001 par value per share (IRD). This represents 65% of the company’s total
100.97MFull value: 100,966,216 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
56%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
PERCEPTIVE ADVISORS LLC 8.9% 9,000,000 0.82% $43,560,000
Caligan Partners LP 5.9% 5,960,972 1.8% $28,851,104
Cormorant Asset Management, LP 5.4% 5,500,000 1.8% $26,620,000
Nantahala Capital Management, LLC 4.5% 4,569,528 1.2% $22,116,516
Boxer Capital Management, LLC 4.5% 4,533,660 1.9% $21,942,914
BIOS Capital Management, LP 3.6% 3,683,429 52% $17,827,796
VANGUARD CAPITAL MANAGEMENT LLC 3.2% 3,273,451 0% $15,843,503
MARSHALL WACE, LLP 3.1% 3,161,606 0.01% $15,302,172
Trails Edge Capital Partners, LP 2.4% 2,411,657 1.7% $11,672,420
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.2% 2,254,996 0.02% $10,914,181
GEODE CAPITAL MANAGEMENT, LLC 1.8% 1,810,968 0% $8,767,030
STATE STREET CORP 1.3% 1,330,398 0% $6,439,126
AWM Investment Company, Inc. 1% 1,051,936 0.49% $5,091,370
Logos Global Management LP 0.99% 1,000,000 0.28% $4,840,000
Affinity Asset Advisors, LLC 0.89% 900,000 0.25% $4,356,000
GOLDMAN SACHS GROUP INC 0.87% 877,876 0% $4,248,920
GREAT POINT PARTNERS LLC 0.77% 776,881 0.99% $3,760,104
Opaleye Management Inc. 0.74% 750,000 0.41% $3,630,000
VANGUARD PORTFOLIO MANAGEMENT LLC 0.73% 734,419 0% $3,554,588
Woodline Partners LP 0.66% 661,729 0.01% $3,202,768
VANGUARD FIDUCIARY TRUST CO 0.53% 538,986 0% $2,608,692
ACUTA CAPITAL PARTNERS, LLC 0.51% 514,110 1.9% $2,488,292
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.35% 350,141 0% $1,694,682
XTX Topco Ltd 0.28% 287,409 0.02% $1,391,060
Propel Bio Management, LLC 0.27% 270,036 0.73% $1,306,974

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
24
Headline period
Q3 2026
Rows shown
1-24 of 24
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 65,316,626 $316,118,732 +$82,682,604 $4.84 78
2026 Q2 57,511,923 $236,380,475 +$48,003,889 $4.11 103
2026 Q1 44,292,526 $201,532,694 +$79,524,140 $4.55 77
2025 Q4 27,812,069 $55,903,061 +$17,653,005 $2.01 58
2025 Q3 19,026,274 $31,911,867 +$2,765,658 $1.65 46
2025 Q2 17,503,196 $16,482,508 +$2,741,389 $0.94 43
2025 Q1 14,560,311 $14,686,745 +$11,049,669 $0.98 46
2024 Q4 3,678,848 $4,378,207 +$106,956 $1.19 42
2024 Q3 2,531,596 $3,315,513 -$283,780 $1.31 37
2024 Q2 2,696,097 $4,126,103 -$1,250,857 $1.53 37
2024 Q1 3,374,307 $6,780,798 -$925,460 $2.01 48
2023 Q4 3,712,141 $11,173,334 -$177,249 $3.01 48
2023 Q3 3,768,545 $12,624,748 +$43,437 $3.35 50
2023 Q2 3,675,838 $15,952,413 +$1,001,477 $4.34 49
2023 Q1 3,457,077 $12,962,551 +$1,457,390 $3.75 40
2022 Q4 3,099,588 $10,946,085 +$1,241,957 $3.53 34
2022 Q3 2,825,667 $5,686,000 +$828,901 $2.01 33
2022 Q2 2,407,242 $4,623,000 +$385,937 $1.92 35
2022 Q1 2,052,047 $6,623,000 -$430,212 $3.23 33
2021 Q4 2,169,473 $8,073,000 +$1,421,030 $3.73 32
2021 Q3 1,679,507 $8,621,000 +$3,116,790 $5.15 26
2021 Q2 1,038,443 $5,482,000 +$532,990 $5.28 28
2021 Q1 912,180 $5,265,087 -$7,635,114 $5.81 21
2020 Q4 2,209,512 $14,469,013 +$1,044,013 $6.52 9
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .